Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study

Published:October 09, 2019DOI:


      • The role of SCS in PSROC is still controversial.
      • BRCAmut patients who underwent SCS before platinum-based chemotherapy and olaparib maintenance had an increased TFST and PRS.
      • Indication to SCS should be individualized.



      The role of secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer (PSROC) is still controversial. We investigated the role of SCS in PSROC patients with BRCA1/2 mutation (BRCAmut) who received platinum-based chemotherapy followed by olaparib maintenance.


      This is a case-control study. Patients with first PSROC admitted to our Gynecologic Oncology Unit between 2014 and 2018 were identified. Main eligibility criteria: positive BRCA1/2 germline or somatic mutation status and olaparib maintenance at primary recurrence after response to platinum-based chemotherapy. Cases were those who received SCS followed by medical treatment (SCS-CT-OLA, group 1), controls were those who received medical treatment alone (CT-OLA, group 2).


      Overall, 46 patients were identified; 23 (50%) BRCAmut women undergoing SCS followed by platinum-based chemotherapy and olaparib maintenance were matched with 23 (50%) BRCAmut women who only received medical treatment. Groups were well balanced: no statistical differences were found with regard of age, mutational status, treatment’s approach at diagnosis, timing and patterns of disease presentation at recurrence. Median time to first subsequent therapy (TFST) was significantly longer in the SCS-CT-OLA than in the CT-OLA group (42 months vs 16 months; p = 0.05). Also, SCS-CT-OLA patients had the best post-recurrence survival (PRS), with a 3-year PRS of 79% in SCS-CT-OLA group versus 42% in CT-OLA group (p = 0.02).


      SCS increases TFST and PRS in PSROC patients with BRCAmut candidate for olaparib maintenance after platinum-based chemotherapy. Prospective studies are needed. In the era of personalized medicine, indication to SCS should be individualized.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics.
        CA Cancer J. Clin. 2018; 68 (2018): 7-30
        • Pisano C.
        • Bruni G.S.
        • Facchini G.
        • et al.
        Treatment of recurrent epithelial ovarian cancer.
        Ther. Clin. Risk Manag. 2009 Aug; 5: 421-426
        • Mirza M.R.
        • Monk B.J.
        • Herrstedt J.
        • et al.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N. Engl. J. Med. 2016; 375 (25): 2154-2164
        • Pujade-Lauraine E.
        • Ledermann J.A.
        • Selle F.
        • et al.
        Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18 (26): 1274-1284
        • Coleman R.L.
        • Oza A.M.
        • Lorusso D.
        • et al.
        Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 1949-1961
        • Lorusso D.
        • Mancini M.
        • Di Rocco R.
        • et al.
        The role of secondary surgery in recurrent ovarian cancer.
        Int J Surg Oncol. 2012; 2012613980
        • Du Bois A.
        • Vergote I.
        • Ferron G.
        • et al.
        Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.
        J. Clin. Oncol. 2017; 35: 5501
        • Coleman R.
        • Enserro D.
        • Spirtos N.
        • et al.
        A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG Oncology/Gynecologic Oncology Group (GOG) study.
        J. Clin. Oncol. 2018; 36: 5501
        • Coleman R.
        • Enserro D.
        • Herzog T.J.
        • et al.
        A phase III randomized controlled trial of secondary cytoreductive surgery (SCS) followed by platinum-based chemotherapy (PC) platinum-sensitive, recurrent ovarian cancer (PSOC)—surgical parameters.
        in: International Gynecologic Cancer Society. Kyoto, Japan2018
        • Fagotti A.
        • Fanfani F.
        • Rossitto C.
        • et al.
        A treatment selection protocol for recurrent ovarian cancer patients: the role of FDGPET/CT and staging laparoscopy.
        Oncology. 2008; 75: 152-158
        • Fanfani F.
        • Monterossi G.
        • Fagotti A.
        • et al.
        Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.
        Ann. Surg. Oncol. 2015; 22: 649-654
        • Ferrandina G.
        • Legge F.
        • Salutari V.
        • et al.
        Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations.
        Eur. J. Cancer. 2006; 42: 2296-2302
        • Harris Paul A.
        • Taylor Robert
        • Thielke Robert
        • et al.
        Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support.
        J. Biomed. Inform. 2009 Apr; 42: 377-381
        • Mathews C.A.
        • Moore K.N.
        • Colombo N.
        • et al.
        Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial.
        J. Clin. Oncol. May 20 2019; 37 (5541-5541)
        • Goldie J.H.
        • Coldman A.J.
        A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
        Cancer Treat Rep. 1979; 63: 1727-1733
        • Marchetti C.
        • De Leo R.
        • Musella A.
        • et al.
        BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study.
        Ann. Surg. Oncol. 2018 Nov; 25: 3701-3708
        • Pujade-Lauraine E.
        • Colombo N.
        • Glasspool R.
        • et al.
        OReO/ENGOT Ov-38: a Phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer.
        Ann. Oncol. 2017; 28 (NCT03106987): v330-v354